101095-67-4

Basic information

• Product Name: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea
• Synonyms: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea
• CAS NO: 101095-67-4
• Molecular Formula: C₁₅H₁₃ClN₂O₂
• Molecular Weight: 288.72892
• Mol File: 101095-67-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea(101095-67-4)
• EPA Substance Registry System: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea(101095-67-4)

Safety Data

• Hazardous Substances Data: 101095-67-4(Hazardous Substances Data)

Upstream product

• 104-12-1 p-chlorphenylisocyanate 
• 99-92-3 p-aminobenzophenone 

Downstream Products

• 1067638-91-8 1-(4-chlorophenyl)-3-{4-[(2E)-3-(3,4-dichlorophenyl)prop-2-enoyl]phenyl}urea 

Relevant articles and documents

Synthesis, molecular docking, and biological activities of new cyanopyridine derivatives containing phenylurea

A new class of cyanopyridine derivatives (10a–e and 11a–e) containing the phenylurea unit was synthesized and tested against some metabolic enzymes including acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase (α-Gly). The new cya

Synthesis and Biological Evaluation of Novel 1-(4-(Hydroxy(1-oxo-1,3-dihydro-2H-inden-2-ylidene)methyl)phenyl)-3-phenylurea Derivatives

A series of novel phenylurea containing 2-benzoylindan-1-one derivatives 3a?–?3j were synthesized from the reaction of phenylurea-substituted acetophenones 1a?–?1j with phthalaldehyde 2 under mild reaction conditions in good yields. All synthesized compou

DIARYL UREAS AS CB1 ANTAGONISTS

Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.